Back
Vinpo-15
Supports optimal brain function*
- Supports visual and hearing health
- A great alternative to ginkgo biloba
- Promotes healthy cognitive and neurological function
- Improves the flow of oxygen and nutrients to the brain
AOR’s Vinpo-15 is vinpocetine, which is a modified alkaloid compound originally found in the periwinkle plant (also known as Vinca minor) that helps support brain function and cognitive health. Our formula works to improve brain metabolism by increasing cerebral microcirculation and the delivery of glucose and oxygen across the blood-brain barrier while increasing ATP (cellular energy) synthesis.
The human brain is the most complex and important organ in the body, as it is responsible for our memories, thinking, learning, actions, reactions, feelings, and numerous other vital functions. It has the capacity to generate about 23 watts of power when awake and it uses 20% of the blood in our body. Brain health is crucial for our health in general. In fact, as per an AARP study, brain health is the second most important element in maintaining health as we age. With the brain at the center of our body functions, it is no surprise that keeping it sharp and properly functioning is vital for our overall health.
Vinpocetine provides benefits similar to those of ginkgo biloba in that both help support blood flow as well as oxygen and nutrient delivery to the brain. However, unlike ginkgo, vinpocetine doesn’t reduce blood flow elsewhere in the body. It has been suggested that vinpocetine can directly increase ATP levels in red blood cells, which promotes optimal energy levels in the brain.
AOR Advantage
AOR’s Vinpo-15 is an excellent choice for those looking to support their memory and brain function as they age, currently supplementing with Ginkgo biloba, and who are particularly concerned with ginkgo’s blood-thinning effects.
Vinpo-15 is vinpocetine, a compound found in voacanga. Studies show that vinpocetine has similar benefits to Ginkgo biloba.*
AOR™ guarantees that all ingredients have been declared on the label. Made without wheat, gluten, corn, nuts, peanuts, sesame seeds, sulfites, mustard, soy, dairy, eggs, fish, shellfish or any animal byproduct.
Take one capsules one to three times a day with food, or as directed by a qualified health care practitioner.
Do not take if you are pregnant or lactating, have a medical condition (high or low blood pressure, cardiac arrhythmia, dementia, or have suffered a stroke), or if you’re taking any medication (blood thinners). Keep out of reach of children. Hypersensitivity is known to occur, and some people may experience anxiety, gastrointestinal discomfort, dizziness or headaches, in which case, discontinue use.
- Cognitive function
- Neurological protection
- Cerebrovascular health
- Hearing function
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
† Daily value not established.
Other Ingredients: microcrystalline cellulose and sodium stearyl fumarate.
Capsule: hypromellose and purified water.
Afon’kin VIu, Dobretsov KG, Sipkin AV. [The new scheme of cavinton application to the treatment of chronic neurosensory loss of hearing]. Vestn Otorinolaringol. 2009;(6):69-70.
Balestreri R, Fontana L, Astengo F. A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J Am Geriatr Soc. 1987 May;35(5):425-30.
Chukanova EI. [Efficacy of cavinton in the treatment of patients with chronic blood flow insufficiency. Russian multicenter clinical-epidemiological program “CALIPSO”]. Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(12):49-52.
Fischhof PK, Moslinger-Gehmayr R, Herrmann WM, et al. Therapeutic efficacy of vincamine in dementia. Neuropsychobiology. 1996;34(1):29-35.
Kahan A, Olah M. Use of ethyl apovincaminate in ophthalmological therapy. Arzneimittelforschung. 1976;26(10a):1969-72.
Kiss B, Karpati E. Mechanism of action of vinpocetine. Acta Pharm Hung. 1996 Sep;66(5):213-24.
Konopka W, Zalewski P, Olszewski J, et al. Treatment results of acoustic trauma. Otolaryngol Pol. 1997;51 Suppl 25:281-4.
Molnar P, Gaal L, Horvath C. The impairment of long-term potentiation in rats with medial septal lesion and its restoration by cognition enhancers. Neurobiology (Bp). 1994;2(3):255-66.
Nagy Z, Vargha P, Kovács L, Bönöczk P. Meta-analysis of Cavinton. Praxis. 1988 Sep; 7(9):63-8.
Pliushko DG, Sobko EG. Drug therapy of initial open-angle glaucoma. Oftalmol Zh. 1989;(2):72-4.
Subhan Z, Hindmarch I. Psychopharmaco-logical effects of vinpocetine in normal healthy volunteers. Eur J Clin Pharmacol. 1985;28(5):567-71.
Ueyoshi A, Ota K. Clinical appraisal of vinpocetine for the removal of intractable tumoral calcinosis in haemodialysis patients with renal failure. J Int Med Res. 1992 Sep;20(5):435-43.
